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Abstract  
To evaluate the shared genetic etiology of type-2 diabetes (T2D) and coronary heart disease (CHD), we 
conducted a multi-ethnic study of genetic variation genome-wide for both diseases in up to 265,678 subjects for 
T2D and 260,365 subjects for CHD. We identify 16 previously unreported loci for T2D and one for CHD, 
including a novel T2D association at a missense variant in HLA-DRB5 (OR=1.29). We show that genetically 
mediated increase in T2D risk also confers higher CHD risk. Joint analysis of T2D loci demonstrated that 24% 
are associated with CHD, highlighting eight variants - two of which are coding - where T2D and CHD 
associations appear to co-localize, and a novel joint T2D/CHD association which also replicated for T2D. 
5 
 
Variants associated with both outcomes implicate several novel pathways including cellular proliferation and 
cardiovascular development. 
 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
Introduction 
The global epidemic of type 2 diabetes mellitus (T2D) is expected to worsen over the coming decades, 
and the number of people with T2D is projected to reach ~592 million by 20351. T2D is also a major vascular 
risk factor for coronary heart disease (CHD) which is the leading cause of death worldwide2. Patients with T2D 
are also at a twofold higher risk of mortality due to CHD compared to those that do not have T2D3, though the 
mechanisms that link T2D with increased risk of CHD remain inadequately understood. Recently, Scott et al 
[ref: 27252175] reported a coding variant in the gene encoding the glucagon-like peptide-1 receptor (GLP1R) 
that was associated with lower fasting glucose, lower T2D susceptibility, and modestly with reduced risk for 
CHD, a result consistent with existing therapeutic perturbation of this gene. This type of result is intriguing, and 
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motivates the search for additional loci with this type of genetic support: association with protective effects for 
both T2D and CHD in humans. Such targets would merit detailed molecular, functional, and therapeutic 
experimentation, but we need first to identify these candidate loci from existing and newly generated data sets.  
Genome-wide association studies (GWAS) have advanced our understanding of the genetic architecture 
individually for each disease, yielding discovery of 87 loci for T2D and 58 loci for CHD4,5. Previous work has 
also demonstrated a genetic correlation between both endpoints6,7, though no study has directly compared 
individual variants beyond established sites across the genome nor examined the pathways that are shared 
between the two outcomes. Regional association for multiple SNPs for both endpoints at a locus has been 
observed (e.g., CDKN2A/2B or APOE)4,5. These initial observations indicate that the genetic pathways that 
connect T2D and CHD may have a modest impact on disease risk, hence requiring large sample sizes to enable 
robust discovery. 
We therefore assembled a discovery association set for T2D comprising of 73,337 T2D cases and 
192,341 controls to first enable discovery of novel loci for T2D. Second, we used additional genetic data on 
90,831 CHD cases and 169,534 controls to identify genetic pathways connected with both outcomes.  
  
Results 
Genome-wide association and replication testing for T2D 
We used genetic data from 48,437 individuals (13,525 T2D cases and 34,912 controls) of South Asian 
(n = 28,139; 9,654 T2D cases and 18,485 controls) and European (n = 20,298; 3,871 T2D cases and 16,427 
controls) descent. We utilized non-overlapping data for T2D from the DIAGRAM consortium4 and conducted 
combined discovery analysis on 198,258 participants (48,365 T2D cases and 149,893 controls). Characteristics 
of the participants, information on genotyping arrays, Q-Q plots and imputation are summarized in 
Supplementary Tables 1-3 and Supplementary Figure 1a and b. After removing known loci, we advanced 
21 novel loci with suggestive association with T2D (P ≤ 5 x 10-6). We performed further testing of these SNPs 
in additional samples of up to 67,420 individuals (24,972 cases and 42,448 controls) of South Asian (n = 
13,960; 4,587 T2D cases and 9,373 controls), European (n = 2,479; 387 T2D cases and 2,092 controls), and 
East-Asian descent (n = 50,981; 19,998 T2D cases and 30,983 controls). Our combined discovery and 
replication analyses included 265,678 participants (73,337 T2D cases and 192,341 controls) (Supplementary 
Figure 1a). In the combined analysis across both stages, 15 SNPs at previously unreported loci for T2D 
obtained genome-wide significance (fixed-effects meta-analysis P < 5 x 10-8, Table 1). A previous report found 
one of our variants (rs10507349) strongly associated with T2D, but we report genome-wide significance for this 
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variant here for the first time8. Population-specific analyses (i.e., Europeans only or South Asians only) 
identified one additional locus where a sentinel variant obtained genome-wide significance in only European 
participants (Table 1, Figure 1, Supplementary Figures 2 and 3, and Supplementary Tables 4 and 5). Aside 
from this case, there was little evidence of heterogeneity of effect between the ancestry groups in either our 
primary genetic analyses or across the two stages (Supplementary Figure 2). We replicated previously 
reported associations with T2D at 59 loci at genome-wide significance; a further 25 known loci were associated 
with T2D at P < 0.05 (Figure 1 and Supplementary Table 4). We did not observe association at 3 loci 
(rs76895963, rs7330796, rs4523957) in our overall meta-analyses, owing to their previous discovery in subjects 
of East Asian ancestry (Supplementary Table 4). To nominate candidate genes and pathways, we obtained 
expression quantitative trait locus (eQTL) data from the MuTHER consortium and GTEx (v6, Supplementary 
Table 6)9,10. These data suggest a candidate gene at two loci (ITFG3 and PLEKHA1) where the lead eQTL 
association strongly tagged the T2D association (r2 = 1.0). 
  
Coding variants at new genetic loci 
To identify coding variants that may influence protein structure at unreported T2D loci, we obtained 
data on up to 31,207 individuals (9,500 T2D cases, 21,707 controls) of South Asian (7,832 T2D cases, 16,703 
controls) and European origin (1,668 T2D cases, 5,004 controls) (Methods) genotyped on the Exome-chip11. 
We investigated 505 variants captured by the exome-chip within ±250kbp flanking regions of the sentinel 
SNPs. We identified one missense variant in HLA-DRB5 (rs701884), that was associated with T2D risk at close 
to exome-wide levels of significance (fixed-effects meta-analysis P < 2 x 10-7) (Supplementary Table 7). The 
missense variant was found to have a relatively stronger impact on disease risk compared to the lead non-coding 
variant. At HLA-DRB5 the odds ratio (OR) for T2D for the missense variant (rs701884) was 1.29 (95% CI: 1.23 
- 1.35; P = 4.8 x 10-7) compared to the T2D OR of 1.06 (95% CI: 1.04-1.08; P = 2.1 x 10-10) for the non-coding 
variant (rs2050188). Existing knowledge on gene function for all novel loci is summarized in Supplementary 
Table 8. 
  
Variant association with traits and circulating biomarkers 
To help understand the underlying biological mechanisms, we examined the association of genetic 
variation at newly discovered loci with a range of phenotypes and biomarkers (n = 70 traits) using publicly 
available resources (Supplementary Table 9). We also used an association screen against a panel of 105 
phenotypic traits measured in the PROMIS study in up to 17,542 participants (Supplementary Table 10)12. For 
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these 17 loci, we conducted 4,275 variant-phenotype analyses resulting in a Bonferroni-adjusted significance 
threshold of P = 1.5 x 10-5. Allelic variation that increased T2D risk was associated at TMEM18 with increased 
BMI (P = 4.39 x 10-52), BMI in childhood (P = 7.95 x 10-12), obesity (P = 2.50 x 10-25) and obesity in childhood 
(P = 2.85 x 10-20); at KL, with increased fasting glucose (P = 2.26 x 10-8); at PLEKHA1 with increased risk of 
neovascular disease (P = 2.71 x 10-94); at SLC22A1, with increased Lp(a) levels (P = 5.10 x 10-6); at CMIP, with 
decreased HDL-C (P = 1.32 x 10-19), increased triglycerides (P = 2.14 x 10-7) and decreased adiponectin (P = 
1.87 x 10-18). 
 
Genetic risk for T2D and CHD shared at established loci 
We next examined the relationships of sentinel T2D SNPs with the risk of CHD at all T2D loci 
(Supplementary Table 11). For analyses in relation to CHD, we used data on up to 260,365 participants 
(90,831 CHD cases and 169,534 controls) (Methods). We found allelic variation at 17 T2D loci to be nominally 
associated with CHD risk at P < 0.01, which was more than expected (17 of 106 T2D SNPs, binomial test P = 
5.9 x 10-13). In one case, we found that the T2D sentinel SNP rs7578326 (the IRS1 locus) was associated with 
both T2D and CHD at genome-wide levels of significance (Supplementary Table 11 and Supplementary 
Figure 4). To the best of our knowledge, this is the first report of genetic variation at IRS1 associated with CHD 
beyond a reasonable doubt (Supplementary Note)5. In what follows, we investigate the relationship between 
these two endpoints in more detail. 
 
Genetically elevated T2D risk overall increases CHD risk 
First, we examined if elevated T2D risk conferred a higher risk of CHD using the framework of 
Mendelian Randomization13-15 and examined if all genetic T2D risk pathways impact CHD susceptibility in a 
similar way. We calculated genetic risk scores comprising collections of SNPs associated with T2D and 
potentially a range of cardiometabolic traits (Methods). These analyses underscore three key findings. First, a 
genotype risk score based on variants exclusively associated with increased risk of T2D (Methods, 
Supplementary Table 12 and 13) was significantly associated with increased CHD risk (OR = 1.26, Wald-test 
P = 3.3 x 10-8), supporting a causal role for T2D in CHD etiology in a directionally consistent manner 
(Supplementary Table 14). Second, T2D risk scores that involved variants based on their association with 
established risk factors for CHD (blood pressure, BMI, lipids and anthropometric traits, Supplementary Table 
13) revealed significant differences in their estimated effects in relation to CHD (OR = 1.07 to 1.43, Cochran’s 
Heterogeneity Test P = 1.4 x 10-5), indicating that the genetic mechanisms and underlying pathways that 
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increase risk of T2D do not uniformly impact CHD risk in the same manner (Supplementary Table 14). 
Finally, in contrast to these scores, variants associated with T2D and glucose or insulin-related traits, but not 
other traits, were not associated with CHD (OR = 1.07, Wald-test P = 0.06) (Supplementary Table 14); though 
could be due to reduced power of this instrument relative to others, as has been observed previously14. These 
analyses indicate that pathways segregating genetic susceptibility for T2D may not have an equivalent impact 
on CHD risk. 
 
Genetic risk for T2D and CHD shared genome-wide 
We next looked for enrichment in the consistency of the risk allele associated with both T2D and CHD 
across the genome. In our meta-analyses, of the 1,260 variants associated with T2D at a P < 5 x 10-8, we found 
that 76.1% of the T2D risk alleles were associated with higher risk of CHD as well, in comparison with an 
expectation of 50% under the null hypothesis (binomial test P = 2.6 x 10-33, Table 2). In contrast, variants 
associated with CHD at P < 5 x 10-8 were not enriched for directional consistency in allelic associations with 
T2D (48.2 vs 50% expected, binomial test P = 0.79). Among the loci nominally associated with T2D and CHD 
(P < 0.05 but excluding P < 5 x 10-8 associations above), 81.8% of the allelic variation associated with both the 
outcomes in a directionally consistent manner (binomial test P < 10-100). Furthermore, of the allelic variation 
that was not associated with both T2D and CHD at a P-value > 0.05, only 50.6% of the allelic variation 
(compared to 50% expected under the null hypothesis) was associated with the two outcomes in a directionally 
consistent manner (Table 2). To rule out any biases introduced due to allelic variations at a limited set of loci 
associated with both CHD and T2D, we conducted sensitivity analyses using genome-wide variants pruned for 
LD and found results consistent for an overall enrichment of loci associated with both T2D and CHD in a 
directionally consistent manner (Supplementary Table 15).  
 
Joint test reveals an additional locus for T2D and CHD 
Motivated by the enrichment of directionally consistent associations of allelic variation between T2D 
and CHD SNPs, we performed a genome-wide association scan which modeled the joint distribution of 
association with both T2D and CHD (T2D-CHD, Methods), a test to help improve power for discovery of 
novel loci that are associated with both the outcomes (Supplementary Figure 5). After verifying that our test 
statistic was calibrated  (Supplementary Figure 6a and 6b), we used this approach to identify a set of loci that 
were associated with both T2D and CHD (both traits with fixed effects meta-analysis P < 10-3), and were 
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overall associated at genome-wide levels of significance (bivariate P < 5 x 10-8, Supplementary Table 16). 19 
loci met these criteria, which included many established loci for T2D or CHD.  
We identified one previously unreported association near CCDC92 (bivariate P = 2.7 x 10-9, 
Supplementary Figure 7a). The sentinel variant (rs825476) was associated with both T2D (fixed effects meta-
analysis P = 2.2 x 10-6) and CHD (fixed effects meta-analysis P = 2.9 x 10-7) (Supplementary Figure 7b and 
7c); rs825476-T at this locus increased risk for both the outcomes. To demonstrate conclusive association of 
rs825476 with T2D, we sought additional replication data from 8 additional cohorts, comprising 21,560 T2D 
cases and 42,814 controls. We observed marginal replication for this variant in those data alone (OR = 1.04, 
95% CI: 1.01 - 1.07; fixed effects meta-analysis P = 5.5 x 10-3), and obtained genome-wide significance when 
combined with the previous data (OR = 1.04, 95% CI: CI: 1.03 - 1.06; fixed effects meta-analysis P = 4.3 x 10-
8), Supplementary Figure 7b). Analyses conditioned on the lead SNP accounted for all the residual joint T2D-
CHD association in the region (Methods), indicated that the underlying genetic associations for both endpoints 
co-localize to a shared genetic risk factor potentially tagged by the sentinel SNP (Supplementary Figure 8). 
rs825476-T allele also increased the expression of CCDC92 in the subcutaneous adipose tissue 
(Supplementary Table 6) in eQTL analyses conducted in the MuTHER consortium and GTEx [8,9], 
suggesting a possible candidate gene for the association.  
We sought to reduce our list to a subset of loci that co-localized the T2D and CHD associations to a 
single underlying genetic risk variant by conducting formal co-localization analyses (Methods). 8 of these 19 
met this criterion, and at 7 of those 8 loci, the risk allele for T2D also increased the risk for CHD (Table 3). 
This included loci with known associations with T2D (TCF7L2, HNF1A, and CTRB1/2) as well as previously 
unreported T2D loci reported here (MIR17HG and CCDC92), or known association with CHD (MRAS and 
ZC3HC1). Interestingly, this set of directionally consistent loci included coding variants in two transcription 
factors: the missense variant(s) I27L in HNF1A, and R326H in ZC3HC1. At the APOE locus, where the effect 
of association for T2D and CHD risk was opposite, localization was observed at rs4420638, but the tagging 
among the lead sentinel SNPs was incomplete, making it challenging to distinguish between multiple 
conditionally independent variant associations with both traits versus partial tagging of a single, common 
association. At the IRS1 locus, while we found rs7578326 to be associated with both T2D and CHD (P < 5 x 10-
8), formal co-localization analyses failed to identify a single underlying genetic risk factor for the two outcomes 
at this locus. One possibility is that multiple alleles (and haplotypic variability) may be masking clear 
localization of associations.  
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Next, we used biomarker data to help understand the mechanisms linking T2D and CHD at two novel 
loci discovered through bivariate scan, MIR17HG, and CCDC92. The region around CCDC92 segregates 
numerous cardiometabolic trait associations, including T2D (rs1727313)8, HDL-C (rs4759375, rs838880), 
triglycerides (rs4765127)16, and waist-hip ratio adjusted for body mass index (rs4765219)17. However, variants 
in these previous reports were not strongly linked to our sentinel SNP (r2 < 0.02 in all cases). The risk variant 
for T2D-CHD at the CCDC92 locus also decreased HDL-C levels (fixed effects meta-analysis P = 2.2 x 10-9) in 
analyses by the Global Lipids Genetics Consortium (GLGC)16; this variant was in partial linkage with a variant 
(rs10773049, r2 = 0.6 and 0.3 in Europe and South Asia, respectively) previously known for association with 
body mass index. MIR17HG appeared to harbor only modest associations with HDL (fixed effects meta-
analysis P = 1.3 x 10-4), fasting insulin levels (P = 6.4 x 10-4) and HOMA-IR (P = 7.9 x 10-4).  
 
We also examined association at APOE where the T2D risk allele was associated with decreased CHD 
risk. The T2D risk allele was also found associated with increased HDL-C (fixed effects meta-analysis P = 1.72 
x 10-21), decreased LDL-C (P = 1.51 x 10-178), decreased total cholesterol (P = 1.14 x 10-149), decreased 
triglycerides (P = 1.55 x 10-14),  reduced LDL particle size (P =  3.80 x 10-11), increased waist-hip ratio (P = 
1.80 x 10-6, BMI-adjusted), and neovascular disease (P = 2.78 x 10-8).  
 
Joint T2D-CHD associations highlight novel pathways 
We next aimed to identify a subset of highly connected loci that indicate unidentified pathways that 
jointly related to T2D-CHD. To achieve this, we used results from our bivariate T2D-CHD association scan and 
pruned SNPs for LD to obtain a set of unlinked regions across the genome (r2 < 0.05). From this list, we 
selected 299 LD independent SNPs that were found associated with T2D-CHD in our bivariate scan (P < 0.001, 
Supplementary Table 17 and 18) and sought to prioritize candidate genes implicated in the association using 
the text-mining approach, GRAIL18. 79 out of 299 regions were found to have prioritized specific genes in 
associated intervals (GRAIL P < 0.05), significantly more overall than expected (26.4%, binomial test P < 10-
34). Next, protein-protein interaction connectivity analysis among these 79 genes19 demonstrates more direct and 
indirect connections than expected (permuted P < 10-4, Methods), thus motivating us to focus on this subset for 
further analysis. Several plausible candidates from this list emerge, including the hepatic glucose transporter 
SLC2A2, the Adipocyte fatty-acid-binding protein aP2, Lipin-1, PGC-1β, and the Free fatty acid receptor 1 
FFAR1, among others (Supplementary Table 18). 
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We next performed ontology analysis on the set of 79 genes that emerged from T2D-CHD bivariate scan 
for connectivity20. To compare our findings, we also conducted similar ontological analysis on loci identified 
for T2D or CHD in previous GWAS for each of these traits. As expected, ontological analysis of established 
T2D loci alone indicated robust enrichment of diabetes, hyperglycemia, and insulin resistance disease 
annotations (enrichment test P < 10-55), as well as enrichment for pathways related to insulin secretion and 
transport, glucose homeostasis, and pancreas development (all P < 10-9). Also as expected, ontological analysis 
of CHD loci alone demonstrated robust enrichment of disease annotations related to coronary disease, 
myocardial infarction, and arteriosclerosis (P < 10-36), as well as enrichment for pathways related to lipid 
homeostasis and cholesterol transport (P < 10-8). Both sets of pathways and biological processes are 
etiologically relevant for each of the disease outcomes. As expected, the analysis of the 79 T2D-CHD 
associated gene intervals identified loci that were also modestly enriched for disease ontologies related to 
vascular resistance (P < 10-12), T2D, cardiovascular disease, fatty liver, obesity, gestational hypertension, and 
Pre-eclampsia (all P < 10-5), as well as cancer (P < 10-9). But in contrast to the pathways described above, we 
also observed enrichment for additional pathways related to cardiovascular system development, cell signaling, 
signal transduction, regulation of phosphorylation, and transmembrane receptor protein kinase signaling among 
the categories (adjusted P < 10-7) (Supplementary Figure 9). Collectively, these ontologies suggest that 
developmental or signaling processes may be implicated in jointly modulating the risk of T2D and CHD.  
 
Discussion 
We report the discovery of 17 novel loci for T2D using discovery and replication studies in 265,678 
participants. Using exome-chip data, we were able to identify a coding variant which was more strongly 
associated with T2D risk than the corresponding common variant. Using additional data on 260,365 
participants, we report a novel locus for CHD, and identify genetic loci that are shared between T2D and CHD 
which a subset co-localized to the same genetic variant (e.g., CCDC92, MIR17HG, HNF1A, ZC3HC1, APOE, 
Table 3). Finally, using a bivariate scan for T2D-CHD, genetic association data pointed to new pathways that 
are implicated in the etiology of both the disease outcomes.  
 
Many of the loci discovered in the current meta-analyses suggest novel T2D biology or confirm 
pathways previously implicated in T2D. For instance, MIR17HG, KL, and BCL2L11 have been shown involved 
in cell-survival, apoptosis, and cellular aging, respectively21-23. Genetic variants near KL have also been shown 
associated with fasting glucose levels as well24. TMEM18 is involved in cellular migration; genetic variation 
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near TMEM18 has been shown associated with BMI previously25,26. HLA-DR5 and CMIP play crucial roles in 
immune mediated responses and have been implicated in various immunological disorders27,28. Genetic 
variation near CMIP has been shown associated with plasma HDL-C levels16. Genetic variation at the HLA 
locus (rs9272346) has been previously implicated in type-1 diabetes (T1D); however, we did not find any 
evidence of association of rs9272346 with T2D in our meta-analyses. Additionally, rs9272346 was not in LD 
with the T2D sentinel SNP (rs2050188) at this locus (r2 = 0.06 in EUR and r2 = 0.01 in SA). However, 
rs7111341 has been previously reported as a risk factor for T1D29. We found that rs7111341-T is associated 
with increased risk for T2D, but decreased risk for T1D, a similar pattern of association to a previously 
established association (rs7202877, nearby CTRB1).  
 
The contrasting associations of APOE with T2D and CHD were puzzling. APOE encodes 
apolipoprotein-E found in the chylomicron and intermediate-density lipoprotein (IDLs) that is essential for the 
normal catabolism of lipoprotein constituents. Genetic variation at the APOE locus is associated with major 
lipids and CHD5,16. Here, the T2D risk variant was associated with decreased CHD risk and LDL-C, and 
reduced LDL particle size. These observations are consistent with recent epidemiological and genetic studies 
indicating that reduction in LDL-C levels, a major CHD risk factor, may confer a higher risk of T2D. Evidence 
from a meta-analysis of randomized controlled trials has shown that reduction of LDL-C by statin treatment, 
compared to placebo, led to a higher, but a very small absolute, risk of T2D30. Moreover, genetic variants 
associated with reduced expression of HMG-CoA reductase, the target of statins, and reduced LDL-C levels 
have been shown associated with increased risk of T2D31. Also, two Mendelian Randomization studies 
concluded that genetically mediated decreases in LDL-C associated with a higher risk of T2D32,33. Furthermore, 
it has been shown that genetic variants in the PCSK9 gene that lower LDL-C levels associated with a higher risk 
of T2D, fasting glucose concentration, body weight, and waist-to-hip ratio34. In contrast to the findings from our 
overall meta-analyses that seem to suggest directionally concordant associations for both T2D and CHD for a 
majority of genetic variation, these results suggest that LDL-C may represent one of a small subset of discrete 
pathways that display opposing associations for the two outcomes. These findings underscore how human 
genetics can help focus future investigations on T2D therapeutics that have either neutral or beneficial effects 
on vascular outcomes.  
 
The collection of 79 regions identified through our joint T2D-CHD bivariate scan involves targets of 
existing drugs. This includes icosapent, a polyunsaturated fatty acid found in fish oil, which is FFAR1 and 
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PPARG agonist and a COX-1/COX-2 inhibitor35. The ANCHOR trial showed that icosapent ethyl, marketed as 
the drug Vascepa, has efficacy in lowering triglycerides in patients with high TG levels36 as well as non-HDL-C 
and HDL-C37. A second plausible candidate gene is the adipocyte fatty-acid-binding protein (FABP4, also 
known as aP2). Mouse models deficient in aP2 display protection against atherosclerosis and anti-diabetic 
phenotypes38-40. Moreover, small-molecule inhibition of aP2 has been shown to reduce atherosclerosis, glucose 
and insulin levels, and triglycerides in a mouse model41, inhibition of this pathway through a monoclonal 
antibody also appear efficacious in mouse models42.  
 
Careful evaluation of the pathways or biological process where T2D, CHD, and related traits overlap 
could help to highlight new avenues for therapeutic targeting. First, using gene discovery and biomarker studies, 
we have identified new pathways, outside of the established, glucose and cholesterol homeostatic networks, 
where possibilities of repurposing or plausible gene targets could be investigated in more detail. Second, we 
have found that some genetic variants associated with T2D singly or in aggregate are enriched for associations 
with CHD. With one exception (e.g., pathways involving LDL-C), genetic pathways that increase T2D risk tend 
to overall increase CHD risk. Hence, existing or future therapeutic programs designed for the prevention of T2D 
could be better guided by evidence from genetic studies, either to prioritize targets that have either neutral or 
directionally consistent effects on vascular outcomes, or to review the disease risk profile of existing targets that 
may be under development. Overall, identification of genetic loci associated with both T2D and CHD risk in a 
directionally consistent manner could provide therapeutic opportunities to lower the risk of both outcomes. 
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Online Methods 
 
Study subjects. In the discovery phase, we meta-analyzed data from eight different studies; four 
studies (PROMIS, RACE, BRAVE and EPIDREAM) include participants of South Asian origin 
living in Pakistan, Bangladesh and Canada whereas four studies (FINRISK, MedStar, MDC and 
PennCATH) include subjects of European origin (Supplementary Table 1 and Supplementary 
Note). GWAS/Metabochip data and information on T2D risk was available on 48,437 
individuals (13,525 T2D cases and 34,912 controls) from these eight studies. We further used 
published data from the DIAGRAM consortium and conducted combined discovery analysis on 
198,258 participants (48,365 T2D cases and 149,893 controls). Characteristics of the 
participants, information on genotyping arrays and imputation are summarized in Supplementary 
Tables 1-3. Replication studies were completed in participants enrolled in the LOLIPOP, SINDI, 
SDS, MSSE, TAICHI and BBJ studies (Supplementary Table-1), collectively composed of 
67,420 individuals (24,972 cases and 42,448 controls) who were of South Asian (n = 13,960; 
4,587 T2D cases and 9,373 controls), European (n = 2,479; 387 T2D cases and 2,092 controls), 
and East-Asian descent (n = 50,981; 19,998 T2D cases and 30,983 controls). Hence, our 
combined discovery and replication analyses included 265,678 participants (73,337 T2D cases 
and 192,341 controls). All studies were approved by the relevant institutional review boards and 
all participants provided written informed consent. Further details of the contributing cohorts and 
characteristics of the participants are provided in the Supplementary Note and Supplementary 
Table 1. 
 
Institutional Review Board and Informed consent. All participating studies were approved by 
the relevant local institutional review boards. All participants enrolled in each of the participating 
studies provided informed consent. 
 
Genotyping and quality control in the discovery stage. All studies used a high density 
genotyping array (GWAS / Metabochip) (Supplementary Table 2 and Supplementary Note).  
Quality control procedures were performed for each individual study. Details on study specific 
QC are provided in Supplementary Table 2. Each study individually assessed and controlled for 
any population stratification using principal component analysis.  
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Imputation. In all studies, genomic locations of all variants were first harmonized using the 
NCBI Build 37/UCSC hg19 coordinates. Only studies that contributed GWAS data underwent 
imputation. Imputation of genotypes across the genome was computed using the 1000 Genomes 
Project (phase 1 integrated release 3, March 2012)43. Imputed SNPs were removed if they had:  
(i) a minor allele frequency of < 0.01; (ii) info score of < 0.90; (iii) average maximum posterior 
call < 0.90. Supplementary Table 2 provides further details on the imputation protocol used by 
each of the participating studies. 
 
Statistical analysis in the discovery stage. To test for an association between each SNP and risk 
of T2D, a logistic regression model was computed with adjustment for age, sex, and the first 
study-specific principal components using SNPTEST44. The SNP was modeled under an additive 
genetic model and imputation uncertainty was accounted for under an allele dosage approach.  
Inflation of association statistics was assessed within each study by the genomic control method 
(Supplementary Table 3 and Supplementary Figure 1). Variants that were retained in at least 
two studies were meta-analyzed using the METAL program45. We used a weighted inverse 
normal fixed-effects method, weighting by sample size; heterogeneity was assessed by the 
Cochran's Q statistic and the I2 heterogeneity index. Pairwise linkage disequilibrium between 
SNPs was assessed and visualized using the 1000 Genomes European reference panel43. 
Regional association plots were visualized using the LocusZoom software. After removing 
regions harboring known loci, the top associated SNP and one or more SNPs based on linkage 
disequilibrium with the lead variant found in association with any of the above phenotypes (P < 
5?10-6) were selected for the replication studies.  
 
Analyses in the replication stage. Studies that participated in the replication stage had 
conducted genotyping on GWAS or Metabochip arrays. The association of SNPs with T2D was 
calculated separately using trend test, with heterogeneity between studies assessed using the 
Cochran's Q statistic. The weighted inverse normal fixed effects meta-analysis was then 
computed to combine the results across all replication studies and with the discovery stage. For 
the combined analysis of discovery and replication data, genome-wide significance was inferred 
at P < 5 x 10-8. 
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Expression QTL and functional prioritization. To determine whether the identified risk 
variants influenced expression of any nearby genes, we accessed a variety of sources, including: 
(i) GTEx cis-eQTL data in all available tissues, including liver, brain, endothelial cells, and 
whole blood9, and (ii) cis-eQTL data for adipose, lymphoblastoid cell lines, and skin from the 
MuTHER consortium10. 
 
Exome-chip analysis. To assess if there are coding variants associated with T2D in the 
proximity of the newly-discovered sentinel T2D SNPs, we performed an Exomechip-based meta-
analysis in four studies (PROMIS, BRAVE, CIHDS-CGPS, and PROSPER) in the ±500 kbp 
region of the sentinel T2D SNPs.  For all the studies, genotyping and QC were done centrally at 
the University of Cambridge, UK. In each study, samples with extreme intensity values, and 
outlying plates or arrays were removed prior to genotype calling. Genotype calling was initially 
performed with optiCall. Samples with call rate (CR) less than (mean CR - 3 standard deviations) 
were removed prior to post-processing optiCall calls with zCall. Scanner specific Z-values 
(calculated using 1,000 samples with the highest optiCall CR) were adopted as they gave the best 
global concordance within each batch. Rare variants (optiCall, Minor Allele Frequency (MAF) < 
0.05) were then post processed with zCall using the scanner specific Z-values. Within each 
genotyping batch, variants were removed if variant CR < 0.97; HWE P < 1x10-6 for common 
variants or HWE P < 1x10-15 for rare variants (MAF < 0.05). Variants within each genotyping 
batch were aligned to human genome reference sequence plus strand and the standardized files 
were used for sample QC. Samples were excluded from each batch/study if sample 
heterozygosity > ±3 standard deviations from the mean heterogeneity or sample call rate >3 
standard deviations from the mean call rate. Variants were further selected based on stringent QC 
thresholds (CR < 0.99; Hardy-Weinberg Equilibrium (HWE) P < 1x10-4) MAF > 0.05 and LD 
pruned (r2 <0.2) for PCA and kinship calculations. Duplicates within each collection (kinship 
coefficient>0.45) and ancestral outliers identified by PCA were removed. Samples and variants 
that failed QC were removed from individual batches. Where studies were analyzed in multiple 
batches, the batches were combined and any SNVs out of HWE across the study were removed. 
Build and strand for each study was checked using checkVCF against build37 plus 
strand.  The reference and alternate alleles were aligned with the reference. Study specific 
analyses were conducted using RAREMETALWORKER46,47 incorporating the kinship matrix 
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and adjusting for age and sex.  In each study, variants with a MAC < 10 were removed before 
meta-analysis. Meta-analysis was done in METAL. In the meta-analysis, the sample-size 
weighted approach was used to estimate the P-values and an inverse-variance weighted approach 
was used to calculate the pooled effect estimates and corresponding standard errors. Study 
specific information is provided in Supplementary Table 19. 
 
Phenome/Biomarker scan analyses. We downloaded online-available GWAS data from 12 
consortia for 70 traits (Supplementary Table 9) and harmonized the genome position to build 
37/hg19.  We then performed a lookup for the 17 newly discovered T2D SNPs using these 
harmonized data sets.  We also performed a phenotypic scan for the same 17 SNPs across 105 
biomarkers measured in the PROMIS participants (Supplementary Table 10). We used a 
Bonferroni-adjusted P-value cut point of 1.7 x 10-5 (= 0.05 / 175 traits / 17 SNPs) to declare 
statistical significance. 
 
Coronary heart disease (CHD) meta-analysis. We assembled 56,354 samples of European, 
East Asian and South Asian ancestries genotyped on the CardioMetabochip to identify genetic 
determinants of CHD. These results were combined with those reported by 
CARDIoGRAMplusC4D to yield analyses comprising of 260,365 subjects (90,831 CHD cases) 
for CHD. The Cambridge MI studies comprised of 16,093 CHD cases and 16,616 unaffecteds 
from the EPIC-CVD study, a case-cohort study recruited across 10 European countries, the 
Copenhagen City Heart Study (CCHS), the Copenhagen Ischemic Heart Disease Study (CIHDS) 
and the Copenhagen General Population Study (CGPS) all recruited within Copenhagen, 
Denmark. The Cambridge MI SAS studies comprised up to 7,654 CHD cases and 7,014 controls 
from the Pakistan Risk of Myocardial Infarction Study (PROMIS) a case-control study that 
recruited samples from 9 sites in Pakistan, and the Bangladesh Risk of Acute Vascular Events 
(BRAVE) study based in Dhaka, Bangladesh. The EA studies comprised 4,129 CHD cases and 
6,369 controls recruited from 7 studies across Taiwan that collectively comprise the TAIwan 
metaboCHIp (TAICHI) Consortium. Samples from EPIC-CVD, CCHS, CIHDS, CGPS, BRAVE 
and PROMIS were all genotyped on a customized version of the Illumina CardioMetabochip 
(manufactured by Illumina, San Diego, USA) referred to as the Metabochip+, in two Illumina-
certified laboratories located in Cambridge, UK, and Copenhagen, Denmark.  TAICHI samples 
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were genotyped using the standard CardioMetabochip. For each study, samples were removed if 
they had a call rate < 0.97, average heterozygosity >±3 standard deviations away from the 
overall mean heterozygosity or their genotypic sex did not match their reported sex. One of each 
pair of duplicate samples and first-degree relatives (assessed with a kinship co-efficient > 0.2) 
were removed. Cardio-metabochip data were also obtained from the Women Health Initiative 
Study and the ARIC study; the two studies underwent same QC as described for the TAICHI 
study. Across all studies, SNP exclusions were based on minor allele frequency (MAF) < 0.01, P 
< 1x10-6 for Hardy-Weinberg Equilibrium or call rate (CR) less than 0.97. 
CARDIoGRAMplusC4D Consortium data were obtained online (see URLs). Only non-
overlapping samples were used for meta-analyses. Fixed effects inverse variance weighted meta-
analysis was used to combine the effects across studies in METAL. 
 
Genetic Risk Score Analysis. We utilized a two-sample MR method48 to estimate effects for a 
multi-SNP genetic instrument by using summary statistics. This method has been previously 
validated to infer causal effects (odds ratio) and associated standard error49. Briefly, association 
data for both T2D and CHD were obtained using data from two separate genome-wide meta-
analyses. For T2D, we used the data from the current meta-analyses; whereas we used data from 
the most recent CHD meta-analyses as described in the Supplementary Note. Using sentinel 
SNPs for all established T2D associations, we identified a set of variants (n=16) exclusively 
associated with T2D, by screening against GWAS catalog of publicly available data50 for 
anthropometric traits (i.e., body mass index (BMI), waist-hip ratio (WHR), waist circumference 
(WC), WHR adjusted for BMI, WC adjusted for BMI, and hip), glucose/insulin (fasting glucose, 
2 hour glucose, fasting insulin, and proinsulin levels), blood lipids (high, low-density lipoprotein 
cholesterol and triglycerides), and blood pressure (systolic and diastolic). We next attempted to 
group the remaining pleiotropic T2D SNPs into different categories based on their observed 
associations for various cardiometabolic intermediate traits (P < 0.01). These groupings 
included: (i) variants associated with glucose/insulin traits only (n=13), (ii) variants associated 
with TG/HDL-C and waist circumference / WHR but not glucose/insulin, blood pressure, LDL-
C, or BMI (n=6), (iii) TG/HDL-C and obesity/anthropometric traits, but not glucose/insulin, 
blood pressure, or LDL-C (n=6), (iv) TG/HDL-C, blood pressure, and BMI, but not 
glucose/insulin or LDL-C (n=8), and (v) TG/HDL-C, blood pressure, BMI, and glucose/insulin 
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but not blood pressure or LDL-C (n=24, Supplemental Table 12). Established T2D SNPs that 
did not fall into any of these categories were excluded. Heterogeneity in odds ratios was assessed 
via Cochran’s Q test for heterogeneity.  
 
T2D and CHD enrichment analysis. We used a binomial distribution with a baseline 
enrichment probability Pb to derive the density for the test statistic E ~ Binomial(n, Pb), where n 
is the number of SNPs in a variant set. E is the number of SNPs with a directionally consistent 
effect on T2D and CHD (the allele that increases the risk for T2D also increases the risk for 
CHD).  Using the SNPs that are not associated with T2D or CHD (P-values ≥ 0.05 for T2D and 
CHD), we calculated the percentage of SNPs with a directionally consistent effect in T2D and 
CHD and used it as an estimate for Pb. We then performed the enrichment analysis in two variant 
sets: (i) the variant set with all variants available and (ii) the variant set with LD-clumped 
variants. The results are shown in Supplementary Table 15. In the LD-clumping procedure, the 
SNPs with more significant T2D P-values were retained as seeds and the other SNPs that were in 
LD (r2 > 0.1 in based on data from the 1000 Genomes Project (Phase 3, v5 variant set) with the 
seed SNPs were removed43. 
 
Estimating the T2D-CHD bivariate normal density. To establish the T2D-CHD bivariate 
normal density, we used all variants that we identified in our analyses on T2D and CHD; we 
further pruned them for LD using the 1000 Genomes project (Phase 3, v5 variant set) to r2 ≤ 0.1 
using PLINK43,51. The reference and alternate alleles of the variants survived LD-pruning were 
retrieved from the same 1000 Genomes VCF file used for pruning, and the variants’ effects on 
CHD and T2D were aligned to their reference alleles. The statistics used to estimate the bivariate 
normal density were produced by using the following formula: 
 
 ???? ? ??? ?????? ? ? ??????????, ???? ? ??? ?????? ? ? ??????????    (1) 
 
where Φ-1 is the inverse-cumulative distribution function of standard normal distribution, PCHD 
and PT2D are the P-values of CHD and T2D respectively, and βCHD and βT2D are the effect sizes of 
the reference allele on CHD and T2D respectively.  Since a successful estimation of the bivariate 
distribution depends on both positive and negative Z-scores, we used the signs of the 
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corresponding effect estimates (β/|β|) to determine the signs of ZCHD and ZT2D.  The distribution 
of ZCHD and ZT2D are shown in Supplementary Figure 5.  Parameters for the bivariate normal 
density were estimated by using the mvn.ub() function in the R package miscF.  The estimated 
bivariate normal density has the following parameter values: 
 ?????????? ? ??????????????????, ? ? ??????? ???????????? ???????   (2) 
 
Two-degree-of-freedom test under the bivariate normal density. Assuming that Z is 
distributed as a Bivariate Normal, e.g., then: 
 ? ? ?????? ? ???????? ?? and ?? ? ???????? ? ?? ? ? ??????? ????,         (3) 
 
where N2(μ, Σ) denotes a bivariate normal distribution with a vector of means μ and 
variance/covariance matrix Σ, and ??? is the chi-square distribution with 2 degrees-of-freedom.  
Using Y as the test statistic, we performed a two-degree-of-freedom test on Z = (ZCHD, ZT2D), and 
our null hypothesis is that a SNP is not associated with any of thw two traits.  Supplementary 
Figure 5 depicts the rejection region of the two-degree-of-freedom test. 
 
Conditional Analysis for CCDC92. We performed approximate conditional analysis for the 
CCDC92 locus using the software package GCTA52. We used the summary meta-analysis data 
for our primary T2D and CHD scans (prior to replication) as data input from each continental 
group (European, South Asian, East Asian). As reference input, we utilized population data from 
the 1000 Genomes Project (version 3) which matched the continental ancestry for the respective 
conditional analysis. We then conditioned on rs825476 – the lead SNP associated with CHD and 
T2D – for each continental group. We then combined summary results from each continental 
group via inverse-weighted fixed-effects meta-analysis. Locus zoom plots for these conditional, 
meta-analyzed association results are presented in Supplementary Figure 8. 
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Co-localization Analysis. To determine if the T2D and CHD association signals co-localized to 
the same genetic variant, we utilized the R package coloc. For each of the 19 loci that met our 
T2D/CHD association criteria, we obtained association data from all SNPs within 500kb around 
the sentinel bivariate associated SNP (Supplementary Table 16). From there, we used the 
coloc.abf() function to calculate the probability that both traits are associated and share a single 
causal variant (H4), using the P-values given from the overall inverse-variance fixed effects 
meta-analysis for T2D (without replication) and CHD, the overall case/control sample sizes for 
both scans, and the allele frequencies for the variant based on all 1000 Genomes data (version 3). 
We call variants co-localized if the H4 co-localization probability was greater than 0.5. 
 
Selection of loci for connectivity and ontology analyses. For T2D, we used the previously 
reported loci4 (n = 87) and the loci discovered in this report (n = 17). For CHD, we used the 
previously reported loci described in the most recent report published by the 
CARDIoGRAMplusC4D consortium (n = 58).  Prioritization of genes from this list of 
established loci for T2D and CHD (Supplementary Table 17) was based on evidence from 
monogenic association with disease53, coding mutations in nearby genes, functional evidence 
implicating genes, or based on the gene nearest to the sentinel SNP. For T2D-CHD associations 
arising from our bivariate scan, we first pruned the dataset for LD (r2 < 0.1). We further selected 
299 LD independent SNPs that were found associated with T2D-CHD with a P < 0.001 in our 
bivariate scan and used them to identify underlying candidate genes using GRAIL18. For protein-
protein interaction connectivity analysis, we used DAPPLE19 on the 79 loci that were found 
significant in GRAIL18. Empirical significance for excess connectivity in protein-protein 
interactions was assessed by 10,000 permutations.  
 
Ontology analysis and drug target annotations. We used the online tool WebGestalt20 to 
perform ontology enrichment analysis. For analysis of the query loci, we nominated genes 
(n=79) that were prioritized from text mining (GRAIL P < 0.05). We also performed ontology 
analyses using separate gene lists for T2D (n=104) and CHD (n=58) loci separately. The 
hypergeometric distribution was used to assess significance, and adjustment for multiple testing 
was controlled using the Benjamini-Hochberg procedure54  implemented in WebGestalt20. 
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Data Availability Statement 
On the date of the publication of the manuscript, summary GWAS estimates for the T2D meta-
analysis and bivariate summary data will be publicly available (see URLs).  
Figure 1. A circular Manhattan plot summarizing the association results for the T2D scan. Black: Previously 
established T2D loci, Red: Previously unreported T2D loci from trans-ethnic meta-analysis, Blue: Previously 
unreported T2D loci from EUR only meta-analysis. 
 
 
 
 
 
 
